176 related articles for article (PubMed ID: 10368657)
1. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
Hihara J; Yamaguchi Y; Minami K; Noma K; Toge T
Anticancer Res; 1999; 19(2A):1077-84. PubMed ID: 10368657
[TBL] [Abstract][Full Text] [Related]
2. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
3. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
4. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
5. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432.
Hironaka K; Yamaguchi Y; Okita R; Okawaki M; Nagamine I
Anticancer Res; 2006; 26(5B):3701-7. PubMed ID: 17094388
[TBL] [Abstract][Full Text] [Related]
6. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
[TBL] [Abstract][Full Text] [Related]
7. Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection.
Arai T; Hiromatsu K; Nishimura H; Kimura Y; Kobayashi N; Ishida H; Nimura Y; Yoshikai Y
Immunology; 1995 Jul; 85(3):381-8. PubMed ID: 7558125
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
Oshikawa T; Okamoto M; Ohe G; Furuichi S; Nishikawa H; Uddin Ahmed S; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
Int Immunopharmacol; 2003 May; 3(5):643-55. PubMed ID: 12757734
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
Hashimoto M; Takashige K; Furuyashiki M; Yoshidome K; Sano R; Kawamura Y; Ijichi S; Morioka H; Koide H; Oku N; Moriya Y; Kusumoto S; Suda Y
Int Immunopharmacol; 2008 Jan; 8(1):12-9. PubMed ID: 18068095
[TBL] [Abstract][Full Text] [Related]
10. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
11. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
12. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients.
Yamaguchi Y; Satoh Y; Miyahara E; Noma K; Funakoshi M; Takashima I; Sawamura A; Toge T
Anticancer Res; 1995; 15(5B):2201-6. PubMed ID: 8572625
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
Kaji R; Yoshida H; Yanagawa T; Sato M
J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
[TBL] [Abstract][Full Text] [Related]
14. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
15. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells.
Okamoto M; Ohe G; Furuichi S; Nishikawa H; Oshikawa T; Tano T; Ahmed SU; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
Anticancer Res; 2002; 22(6A):3229-39. PubMed ID: 12530069
[TBL] [Abstract][Full Text] [Related]
17. IL-10 protects mouse intestinal epithelial cells from Fas-induced apoptosis via modulating Fas expression and altering caspase-8 and FLIP expression.
Bharhani MS; Borojevic R; Basak S; Ho E; Zhou P; Croitoru K
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G820-9. PubMed ID: 17030898
[TBL] [Abstract][Full Text] [Related]
18. Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent.
Oshikawa T; Okamoto M; Tano T; Uddin Ahmed S; Sasai A; Kan S; Moriya Y; Ryoma Y; Saito M; Sato M
Int Immunopharmacol; 2006 May; 6(5):764-73. PubMed ID: 16546707
[TBL] [Abstract][Full Text] [Related]
19. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.
Yamaguchi Y; Miyahara E; Ohshita A; Kawabuchi Y; Ohta K; Shimizu K; Minami K; Hihara J; Sawamura A; Toge T
Br J Cancer; 2003 Nov; 89(10):1876-84. PubMed ID: 14612896
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
Oshikawa T; Okamoto M; Tano T; Sasai A; Kan S; Moriya Y; Ryoma Y; Saito M; Akira S; Sato M
J Immunother; 2006; 29(2):143-50. PubMed ID: 16531815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
